Genomic Health Updates Analysts on Companion Dx Pipeline, New Education Campaign
November 10, 2010
Genomic Health Updates Analysts on Companion Dx Pipeline, New Education Campaign
Genomic Health discussed the status of its ongoing work with Pfizer in renal cancer and suggested it might eventually develop a companion test for Erbitux that gauges mutations "beyond KRAS."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Qiagen's Experience Developing KRAS CDx for Erbitux Yields Lessons for Rx/Dx Development
November 28, 2012 / Pharmacogenomics Reporter - Genomic Health Partners with OncoMed to Grow Companion Dx, NGS Reach
May 9, 2012 / Pharmacogenomics Reporter - Reporting Another Profitable Year, Genomic Health Considers Prostate Cancer Dx Next Big Opportunity
February 8, 2012 / Pharmacogenomics Reporter - Genomic Health Focuses on Oncotype DX Tests for DCIS and Colon Cancer for Future Growth
August 10, 2011 / Pharmacogenomics Reporter - Focusing on Personalized Medicine, Pfizer Reports PGx Data for Several Oncologics at ASCO
June 9, 2010 / Pharmacogenomics Reporter